

TrialNet Explores Plasmid Therapy for Type 1 Diabetes

Phase 1 study now recruiting adults diagnosed in past 4 years

Seattle, Jan 14, 2021 ([IssueWire.com](https://www.issuewire.com)) - TrialNet is testing a new plasmid therapy in adults diagnosed with type 1 diabetes in the past 4 years.

Designed by Novo Nordisk, NNC0361-0041 is a recombinant supercoiled plasmid encoding four human proteins: pre-proinsulin (PPI), transforming growth factor β 1 (TGF- β 1), interleukin-10 (IL-10), and interleukin-2 (IL-2). Preclinical findings show these therapies working together might retrain the immune system to stop attacking insulin-producing beta cells.

This is a Phase 1 study, meaning it is the first time this plasmid is being tested in people. If the study results in no safety concerns, TrialNet plans to conduct a larger study to see if the same treatment can slow or stop disease progression in high-risk individuals prior to type 1 diabetes diagnosis.

To learn more about this study, visit trialnet.org/topple.

About TrialNet

The largest clinical trial network ever assembled to change the course of type 1 diabetes, TrialNet offers free risk screening for relatives of people with type 1 diabetes and innovative clinical studies testing ways to maintain insulin production before and after diagnosis. TrialNet is funded by the National Institutes of Health (NIH), primarily through the [Special Statutory Funding Program for Type 1 Diabetes](#). Visit trialnet.org.

Media Contact

TrialNet

info@trialnet.org

Source : TrialNet

[See on IssueWire](#)